Canada Clears World’s First Plant-Based Covid Vaccine
- Unit of Mitsubishi, Philip Morris crafted the shot with Glaxo
- Vaccine may generate $1 billion in sales, Mitsubishi CEO says
This article is for subscribers only.
The world’s first plant-derived Covid-19 vaccine was cleared for use in Canada, creating a novel immunization to combat the virus from a unit of Mitsubishi Chemical Holdings Corp. and Philip Morris International.
The vaccine named Covifenz was jointly developed by Medicago Inc., a biopharma company owned by Mitsubishi Chemical and Philip Morris and based in Quebec City, and GlaxoSmithKline Plc. It will be available for adults aged 18 to 64, Medicago and Glaxo said in a statement Thursday.